.webp)
Act Now for your ACS Patients
This website contains promotional content and is intended for Healthcare Professionals
Physician and patient perceptions of benefits, risks, and treatment goals of lipid-lowering therapy: Results from GOULD registry.
This review describes the potential benefits of combination treatment and presents data supporting the use of single-pill combination (SPC) for increasing exposure to lipid-lowering treatment (LLT).
Prescription patterns of lipidlowering therapies over time in patients with atherosclerotic cardiovascular disease: Findings from Gould study
Highlights on the most recent real-world data on the use of PCSK9 inhibitors, including those from the Swedeheart and AIFA registries.
Factors associated with time to PCSK9i initiation following hospital discharge for acute myocardial infarction.
The synopsis of a Cochrane Systematic review on PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.